Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2005 Oct 19;2005(4):CD000386.
doi: 10.1002/14651858.CD000386.pub2.

Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria

H M McIntosh  1 , K L Jones
Affiliations
Meta-Analysis

Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria

H M McIntosh et al. Cochrane Database Syst Rev. .

Abstract

Background: Chloroquine (CQ), amodiaquine (AQ), and sulfadoxine-pyrimethamine (SP) are inexpensive drugs, but treatment failure is a problem. Combination therapy may reduce treatment failure. CQ or AQ plus SP are affordable options of combination treatment, but there is debate about their effectiveness.

Objectives: To assess the combination of CQ or AQ plus SP compared with SP alone for first-line treatment of uncomplicated falciparum malaria.

Search strategy: We searched the Cochrane Infectious Diseases Group Specialized Register (April 2005), CENTRAL (The Cochrane Library Issue 2, 2005), MEDLINE (1966 to April 2005), EMBASE (1974 to April 2005), LILACS (1982 to April 2005), Science Citation Index (1981 to April 2005), African Index Medicus (1993 to 1998), and reference lists. We also contacted researchers at relevant organizations and a pharmaceutical company.

Selection criteria: Randomized controlled trials in adults or children with uncomplicated Plasmodium falciparum malaria were eligible for inclusion. The main outcomes of interest were total and clinical failure at day 28 follow up and serious adverse events.

Data collection and analysis: Two people independently applied the inclusion criteria. One author extracted data and another checked them independently. We used relative risk (RR) and 95% confidence intervals (CI).

Main results: Twelve trials (2107 participants) met the inclusion criteria. A meta-analysis of five AQ trials (461 participants) showed a statistically significant reduction in total failure at day 28 with the combination therapy (RR 0.64, 95% CI 0.46 to 0.91), and meta-analysis of three trials (384 participants) showed a significant reduction in clinical failure at day 28 (RR 0.23, 95% CI 0.11 to 0.49). The statistical significance in the total failure analysis was sensitive to losses to follow up. Data from two CQ trials showed no advantage for total failure with combination therapy at day 28. There was no evidence from the included trials of serious adverse events.

Authors' conclusions: The evidence base is not strong enough to support firm conclusions. The available evidence suggests that AQ plus SP can achieve less treatment failure than SP, but this might depend on existing levels of parasite resistance to the individual drugs.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1.1
1.1. Analysis
Comparison 1 Chloroquine (CQ) or amodiaquine (AQ) combined with sulfadoxine‐pyrimethamine (SP) versus SP alone, Outcome 1 Total failure by day 28.
1.2
1.2. Analysis
Comparison 1 Chloroquine (CQ) or amodiaquine (AQ) combined with sulfadoxine‐pyrimethamine (SP) versus SP alone, Outcome 2 Clinical failure by day 28.
1.3
1.3. Analysis
Comparison 1 Chloroquine (CQ) or amodiaquine (AQ) combined with sulfadoxine‐pyrimethamine (SP) versus SP alone, Outcome 3 Total failure by day 14.
1.4
1.4. Analysis
Comparison 1 Chloroquine (CQ) or amodiaquine (AQ) combined with sulfadoxine‐pyrimethamine (SP) versus SP alone, Outcome 4 Clinical failure by day 14.
1.5
1.5. Analysis
Comparison 1 Chloroquine (CQ) or amodiaquine (AQ) combined with sulfadoxine‐pyrimethamine (SP) versus SP alone, Outcome 5 Early treatment failure.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Basco 2002 {published data only}
    1. Basco LK, Same‐Ekobo A, Ngane VF, Ndounga M, Metoh T, Ringwald P, et al. Therapeutic efficacy of sulfadoxine‐pyrimethamine, amodiaquine and the sulfadoxine‐pyrimethamine‐amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bulletin of the World Health Organization 2002;80(7):538‐45. - PMC - PubMed
Bojang 1998 {published data only}
    1. Bojang KA, Schneider G, Frock S, Obaro SK, Jaffar S, Pinder M, et al. A trial of Fansidar plus chloroquine or Fansidar alone for the treatment of uncomplicated malaria in Gambian children. Transactions of the Royal Society of Tropical Medicine and Hygiene 1998;92(1):73‐6. - PubMed
Darlow 1982 {published data only}
    1. Darlow B, Vrbova H, Gibney S, Jolley D, Stace J, Alpers M. Sulfadoxine‐pyrimethamine for the treatment of acute malaria in children in Papua New Guinea. I. Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene 1982;31(1):1‐9. - PubMed
Dinis 1990 {published data only}
    1. Dinis DV, Schapira A. Comparative study of sulfadoxine‐pyrimethamine and amodiaquine + sulfadoxine‐pyrimethamine for the treatment of malaria caused by chloroquine‐resistant Plasmodium falciparum in Maputo, Mozambique [Etude comparative de la sulfadoxine[pyrimethamine et de l'amodiaquine et sulfadoxine‐pyrimethamine dans la traitement du paludisme a plasmodium falciparum chloroquino‐resistant a Maputo, Mozambique]. Bulletin de la Societe de Pathologie Exotique 1990;83(4):521‐7. - PubMed
Dorsey 2002 {published and unpublished data}
    1. Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, Staedke SG, et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 2002;360(9350):2031‐8. - PubMed
    1. Dorsey G, Vlahos J, Kamya MR, Staedke SG, Rosenthal PJ. Prevention of increasing rates of treatment failure by combining sulfadoxine‐pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria. Journal of Infectious Diseases 2003;188(8):1231‐8. - PubMed
Gasasira 2003 {published data only}
    1. Gasasira AF, Dorsey G, Nzarubara B, Staedke SG, Nassali A, Rosenthal PJ, et al. Comparative efficacy of aminoquinoline‐antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. American Journal of Tropical Medicine and Hygiene 2003;68(2):127‐32. - PubMed
Huang 1988 {published data only}
    1. Huang Q, Weichuan O, Jiexian Z, Zhu W, Zhang K, Huang J, et al. Effectiveness of amodiaquine, sulfadoxine‐pyrimethamine, and combinations of these drugs for treating chloroquine‐resistant falciparum malaria in Hainan Island, China. Bulletin of the World Health Organization 1988;66(3):353‐8. - PMC - PubMed
    1. Huang QL, Quyang WC, Zhou JX, Wu Z, Huang JK, Pan XJ, et al. Efficacy of amodiaquine, Fansidar and their combination in the treatment of chloroquine‐resistant falciparum malaria. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi [Chinese Journal of Parasitology and Parasitic Diseases] 1988;6(4):292‐5. - PubMed
Ndyomugyenyi 2004 {published data only}
    1. Ndyomugyenyi R, Magnussen P, Clarke S. The efficacy of chloroquine, sulfadoxine‐pyrimethamine and a combination of both for the treatment of uncomplicated Plasmodium falciparum malaria in an area of low transmission in western Uganda. Tropical Medicine and International Health 2004;9(1):47‐52. - PubMed
Schapira 1988 {published data only}
    1. Schapira A, Schwalbach JF. Evaluation of four therapeutic regimens for falciparum malaria in Mozambique, 1986. Bulletin of the World Health Organization 1988;66(2):219‐26. - PMC - PubMed
Schellenberg 2002 {published data only}
    1. Schellenberg D, Kahigwa E, Drakeley C, Malende A, Wigayi J, Msokame C, et al. The safety and efficacy of sulfadoxine‐pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene 2002;67(1):17‐23. - PubMed
Schwöbel 2003 {published data only}
    1. Schwöbel B, Jordan S, Vanisaveth V, Phetsouvanh R, Christophel E, Phompida S, et al. Therapeutic efficacy of chloroquine plus sulphadoxine/pyrimethamine compared with monotherapy with either chloroquine or sulphadoxine/pyrimethamine in uncomplicated Plasmodium falciparum malaria in Laos. Tropical Medicine and International Health 2003;8(1):19‐24. - PubMed
Staedke 2001 {published data only}
    1. Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, et al. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 2001;358(9279):368‐74. - PubMed

References to studies excluded from this review

Bakyaita 2005 {published data only}
    1. Bakyaita N, Dorsey G, Yeka A, Banek K, Staedke SG, Kamya MR, et al. Sulfadoxine‐pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda. American Journal of Tropical Medicine and Hygiene 2005;72(5):573‐80. - PubMed
Blair 2003 {published data only}
    1. Blair S, López ML, Pineros JG, Álvarez T, Tobón A, Carmona J. Therapeutic efficacy of three treatment schemes in uncomplicated Plasmodium falciparum malaria, Antioquia, Colombia, 2002 [Eficacia terapéutica des tres esquemas de tratamiento de malaria no complicada por Plasmodium falciparum, Antioquia, Colombia, 2002]. Biomédica 2003;23(3):318‐27. - PubMed
Checchi 2004 {published data only}
    1. Checchi F, Piola P, Kosack C, Ardizzoni E, Klarkowski D, Kwezi E, et al. Antimalarial efficacy of sulfadoxine‐pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine‐pyrimethamine in Bundi Bugyo, western Uganda. Tropical Medicine and International Health 2004;9(4):445‐50. - PubMed
Hugosson 2003 {published data only}
    1. Hugosson E, Tarimo D, Troye‐Blomberg M, Montgomery SM, Premji Z, Bjorkman A. Antipyretic, parasitologic, and immunologic effects of combining sulfadoxine/pyrimethamine with chloroquine or paracetamol for treating uncomplicated Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene 2003;69(4):366‐71. - PubMed
Menard 2005 {published data only}
    1. Menard D, Madji N, Manirakiza A, Djalle D, Koula MR, Talarmin A. Efficacy of chloroquine, amodiaquine, sulfadoxine‐pyrimethamine, chloroquine‐sulfadoxine‐pyrimethamine combination, and amodiaquine‐sulfadoxine‐pyrimethamine combination in Central African children with noncomplicated malaria. American Journal of Tropical Medicine and Hygiene 2005;72(5):581‐5. - PubMed
Ogwang 2003 {published data only}
    1. Ogwang S, Engl M, Vigl M, Kollaritsch H, Wiedermann G, Wernsdorfer WH. Clinical and parasitological response of Plasmodium falciparum to chloroquine and sulfadoxine/pyrimethamine in rural Uganda [Klinische und parasitologische Wirksamkeit von chloroquin und sulfadoxin/pyrimethamin bei Falciparum‐malaria im landlichen Uganda]. Wiener Klinische Wochenschrift 2003;115 Suppl 3:45‐9. - PubMed
Pitmang 2005 {published data only}
    1. Pitmang SL, Thacher TD, Madaki JK, Egah DZ, Fischer PR. Comparison of sulfadoxine‐pyrimethamine with and without chloroquine for uncomplicated malaria in Nigeria. American Journal of Tropical Medicine and Hygiene 2005;72(3):263‐6. - PubMed
Salah 2005 {published data only}
    1. Salah MT, Mohammed MM, Himeidan YE, Malik EM, Elbashir MI, Adam I. A randomized comparison of sulphadoxine‐pyrimethamine and combination of sulphadoxine pyrimethamine with chloroquine in the treatment of uncomplicated falciparum malaria in Eastern Sudan. Saudi Medical Journal 2005;26(1):147‐8. - PubMed
Sowunmi 2002 {published data only}
    1. Sowunmi A. A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine‐sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. Annals of Tropical Medicine and Parasitology 2002;96(3):227‐38. - PubMed
    1. Sowunmi A, Fateye BA. Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs. Tropical Medicine and International Health 2003;8(9):783‐92. - PubMed
Talisuna 2004 {published data only}
    1. Talisuna AO, Nalunkuma‐Kazibwe A, Bakyaita N, Langi P, Mutabingwa TK, Watkins WW, et al. Efficacy of sulphadoxine‐pyrimethamine alone or combined with smodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children. Tropical Medicine and International Health 2004;9(2):222‐9. - PubMed
Tarimo 2002 {published data only}
    1. Tarimo DS, Minjas JN, Bygbjerg IC. Sulphadoxine‐pyrimethamine monotherapy in Tanzanian children gives rapid parasite clearance but slow fever clearance that is improved by chloroquine in combination therapy. Tropical Medicine and International Health 2002;7(7):592‐8. - PubMed
Tjitra 1999 {published data only}
    1. Tjitra E, Suprianto S, Anstey NM. Higher gametocyte prevalence following failure of treatment of Plasmodium falciparum malaria with sulfadoxine‐pyrimethamine and the combination of chloroquine plus sulfadoxine‐pyrimethamine: implications for progression of anti‐folate resistance. Transactions of the Royal Society of Tropical Medicine and Hygiene 2002;96(4):434‐7. - PubMed
    1. Tjitra E, Suprianto S, Dyer M, Currie BJ, Anstey NM. Evaluation of the therapeutic efficacy of chloroquine and sulfadoxine‐pyrimethamine in uncomplicated falciparum malaria in eastern Indonesia: High rates of chloroquine treatment failure with poor hematological recovery. American Journal of Tropical Medicine and Hygiene 1999;61 Suppl 3:286‐7.

Additional references

Altman 2001
    1. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Annals of Internal Medicine 2001;134(8):663‐94. - PubMed
EANMAT 2003
    1. East African Network for Monitoring Antimalarial Treatment (EANMAT). The efficacy of antimalarial monotherapies, sulphadoxine‐pyrimethamine and amodiaquine in East Africa: implications for sub‐regional policy. Tropical Medicine and International Health 2003;8(10):860‐7. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2005
    1. Higgins J, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions [updated March 2005]; Appendix 5b. http://www.cochrane.org/resources/handbook/hbook.htm (accessed 18 April 2005).
Ioannidis 2001
    1. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285(4):437‐43. - PubMed
Ioannidis 2004
    1. Ioannidis JP, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz KF, et al. CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781‐8. - PubMed
Jüni 2001
    1. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42‐6. - PMC - PubMed
Kunz 2002
    1. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Methodology Reviews 2002, Issue 4. [DOI: 10.1002/14651858.MR000012] - DOI - PubMed
Loke 2001
    1. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials ‐ a systematic survey. BMC Clinical Pharmacology 2001;1(1):3. - PMC - PubMed
RBM 2001
    1. Global Partnership to Roll Back Malaria. Antimalarial drug combination therapy: report of a WHO technical consultation, 4‐5 April 2001. Geneva: World Health Organization, 2001.
RBM 2003
    1. Global Partnership to Roll Back Malaria. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization, 2003.
Review Manager 4.2 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. - PubMed
Stepniewska 2004
    1. Stepniewska K, Taylor WR, Mayxay M, Price R, Smithuis F, Guthmann JP, et al. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow‐up. Antimicrobial Agents and Chemotherapy 2004;48(11):4271‐80. - PMC - PubMed
Sturchler 1993
    1. Sturchler D, Mittelholzer ML, Kerr L. How frequent are notified severe cutaneous adverse reactions to Fansidar?. Drug Safety 1993;8(2):160‐8. - PubMed
Watkins 1993
    1. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine‐sulfadoxine: selective pressure for resistance is a function of long elimination half‐life. Transactions of the Royal Society of Tropical Medicine 1993;87(1):75‐8. - PubMed
Watkins 2005
    1. Watkins WM, Sibley CH, Hastings IM. The search for effective and sustainable treatments for Plasmodium falciparum malaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations. American Journal of Tropical Medicine and Hygiene 2005;72(2):163‐73. - PubMed
White 1999
    1. White N. Antimalarial drug resistance and combination chemotherapy. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 1999;354(1384):739‐49. - PMC - PubMed
WHO 1965
    1. WHO Scientific Group on Resistance of Malaria Parasites to Drugs. Resistance of malaria parasites to drugs: report of a WHO scientific group [meeting held in Geneva from 13 to 20 October 1964]; World Health Organization Technial Report Series. Vol. 296, Geneva: World Health Organization, 1965. - PubMed
WHO 1967
    1. WHO Scientific Group on Chemotherapy of Malaria. Chemotherapy of malaria: report of a WHO scienific group [meeting held in Geneva from 25 April to 1 ay 1967]; World Health Organization Technical Report Series. Vol. 375, Geneva: World Health Organization, 1967.
WHO 1973
    1. WHO Scientific Group on the Chemotherapy of Malaria and Resistance to Antimalarials. Chemotherapy of malaria and resistance to antimalarials: report of a WHO scientific group [meeting held in Geneva from 17 to 24 October 1972]; World Health Organization Technical Report Series. Vol. 529, Geneva: World Health Organization, 1973. - PubMed
WHO 1990
    1. WHO Scientific Group on the Chemotherapy of Malaria. Practical chemotherapy of malaria: report of a WHO scientific group [meeting held in Geneva from 5 to 12 June 1989]; World Health Organization Technical Report Series. Vol. 805, Geneva: World Health Organization, 1990.
WHO 1996
    1. World Health Organization. Division of Control of Tropical Diseases. Assessment of therapeutic efficacy of antimalarial drugs: for uncomplicated falciparum malaria in areas with intense transmission. Geneva: World Health Organization, 1996.
WHO 2002
    1. World Health Organization. Cluster on Communicable Diseases. Monitoring antimalarial drug resistance: report of a WHO consultation, Geneva, Switzerland, 3‐5 December 2001. Geneva: World Health Organization, 2002.
WHO 2006
    1. World Health Organization, Roll Back Malaria Dept. Guidelines for the treatment of malaria [WHO/HTM/MAL/2006.1108]. Geneva: World Health Organization, 2006.
Wongsrichanalai 2002
    1. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug‐resistant malaria. Lancet Infectious Diseases 2002;2(4):209‐18. - PubMed

References to other published versions of this review

McIntosh 1997
    1. McIntosh H. Chloroquine or amodiaquine combined with sulfadoxine‐pyrimethamine for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 1997, Issue 4. [DOI: 10.1002/14651858.CD000386] - DOI - PubMed
McIntosh 1998
    1. McIntosh HM, Greenwood BM. Chloroquine or amodiaquine combined with sulfadoxine‐pyrimethamine as a treatment for uncomplicated malaria‐‐a systematic review. Annals of Tropical Medicine and Parasitology 1998;92(3):265‐70. - PubMed
McIntosh 2000
    1. McIntosh HM. Chloroquine or amodiaquine combined with sulfadoxine‐pyrimethamine for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000386] - DOI - PubMed
McIntosh 2001
    1. McIntosh HM. Chloroquine or amodiaquine combined with sulfadoxine‐pyrimethamine for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD000386] - DOI - PubMed